载有Nor-LAAM的PLGA微粒用于治疗阿片类药物使用障碍
Diane Ingabire1, Chaolong Qin2, Tuo Meng2
1Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
概括
研究人员开发了持续释放的nor-Levo-α-乙甲醇 (nor-LAAM) 微粒来治疗阿片类药物使用障碍 (OUD). 这种新的配方在动物模型中减少了芬太尼的使用和戒断症状,提供了一个有前途的新OUD治疗方法.
科学领域:
- 药理学和药物输送 药理学和药物输送
- 神经科学是一个神经科学.
- 成 药物 药物 药物 药物
背景情况:
- 阿片类药物使用障碍 (OUD) 由于药物的有效性有限和高剂量过量风险存在重大挑战.
- 新型治疗策略对于改善OUD治疗结果和患者福祉至关重要.
研究的目的:
- 为了探索nor-Levo-α-acetylmethadol (nor-LAAM) 治疗OUD的治疗潜力.
- 开发和表征持续释放或LAAM载荷的聚 (乳糖合甘油酸) (PLGA) 微粒 (MP).
主要方法:
- 开发了使用离子配对 (HIP) 方法与帕莫酸一起使用nor-LAAM加载的PLGAMP.
- 针对粒子大小,药物加载和释放动力学进行了优化MP,识别了配方 (F4).
- 在注射后4周内在体外持续释放和在子体内血水平在注射后15天内进行评估.
主要成果:
- HIP方法产生了高药载荷,最小初始突发释放和持续释放的nor-LAAMMP.
- 配方 (F4) 显示药物负载量为11%的重量,直径为19微米,持续释放超过4周.
- 单次皮下注射F4至少在15天内维持了子的可检测的血和LAAM水平.
结论:
- 持续释放或LAAM国会议员证明了有效OUD治疗的潜力.
- 在芬太尼成的老鼠模型中,nor-LAAM MPs显著减少了药物选择和戒断症状.
- 这种长效的nor-LAAM MP配方为有限的OUD治疗武器库提供了一个有希望的新选择.
相关概念视频
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
271
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
271
01:22Opioid Receptors: Overview
704
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
704
01:25Analgesia and Pain Management
568
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
568
01:15Drug Abuse and Addiction: Pharmacological Phenomena
463
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
463
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
188
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
188